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ABSTRACT
Stromal fibroblasts become altered in response to solid cancers, to exhibit 
myofibroblastic characteristics, with disease promoting influence. Infiltrating 
mesenchymal stem cells (MSC) may contribute towards these changes, but the factors 
secreted by cancer cells that impact MSC differentiation are poorly understood.
We investigated the role of nano-metre sized vesicles (exosomes), secreted by 
prostate cancer cells, on the differentiation of bone-marrow MSC (BM-MSC), and the 
subsequent functional consequences of such changes. Purified exosomes impaired 
classical adipogenic differentiation, skewing differentiation towards alpha-smooth 
muscle actin (αSMA) positive myofibroblastic cells. A single exosomes treatment 
generated myofibroblasts secreting high levels of VEGF-A, HGF and matrix regulating 
factors (MMP-1, −3 and −13). Differentiated MSC had pro-angiogenic functions and 
enhanced tumour proliferation and invasivity assessed in a 3D co-culture model. 
Differentiation was dependent on exosomal-TGFβ, but soluble TGFβ at matched 
dose could not generate the same phenotype. Exosomes present in the cancer cell 
secretome were the principal factors driving this phenotype.
Prostate cancer exosomes dominantly dictate a programme of MSC differentiation 
generating myofibroblasts with functional properties consistent with disease promotion.
INTRODUCTION
Tumourigenesis is a multicellular process dependant 
on intercellular communication and other extracellular 
signals within the microenvironment [1]. Genetically 
transformed cells can manipulate normal cells within the 
milieu, and are reciprocally responsive to such changes 
in a bidirectional manner. A particularly important 
relationship exists between tumour and stromal fibroblast-
like cells, where the proportion of stromal cells is often 
elevated together with changes in stromal cell activation 
states [1–2]. Solid tumours including those of prostate, 
breast, colon and others reveal an accumulation of 
myofibroblastic stromal cells [3] that exert a powerful 
influence on disease initiation, progression, treatment 
response and ultimately, prognosis [4–8]. A better 
understanding of the cross-communication between 
tumour and stromal cells is likely to lead to progress in 
the clinical management of diverse solid tumours.
Cancer associated stroma drive remodelling of tissue 
architecture by altering matrix, and by producing assorted 
growth factors that directly promote tumour growth [9–10], 
and promote processes such as angiogenesis [10–11] and 
metastasis [12]. However, the cellular origin of stromal 
myofibroblasts remains unclear [13], with an assortment 
of possibilities that include tissue resident fibroblasts or 
vascular pericytes, or through epithelial or endothelial 
transition to mesenchymal phenotypes [14]. There may also 
be contributions from infiltrating cells like mesenchymal 
stem cells of adipose or bone marrow origins [15–16].
Mesenchymal stem cells are defined by the 
international society for cellular transplantation (ISCT) as 
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adherent cells positive for CD73, CD90, CD105, CD146 
and negative for haematopoietic markers like CD14 
or CD45 [17]. MSC are multipotent and are capable of 
generating the various cell types of connective tissue 
including; myocytes, neurones, osteoblasts, chondrocytes, 
adipocytes and fibroblasts. Their physiological roles 
include migration into, and repair of inflammatory/
injured tissues [18], and some studies aim to manipulate 
this property as a therapeutic intervention [19]. The intra-
tumoural migratory potential of MSC however, has been 
difficult to assess in humans [20], but migration into 
tumour xenografts, following intra venous administration 
has been documented for prostate [21], colon [22], breast 
[23–24] and other murine cancers models. The presence 
of MSC in human cancer tissue has certainly been 
documented, estimating a proportion of < 1.1% of the total 
cells in prostate for example [21]. In general, MSC which 
naturally arise at tumour sites or those co-administered 
with tumours in model systems exhibit similarities to 
cancer associated stroma in their tumour-promoting effects 
[15–16, 24–25].
Under the influence of secreted factors of 
tumour cell origin, MSC can undergo differentiation 
into myofibroblast-like cells [24]; akin to those of 
cancer-associated stromal cells, and it is this form of 
differentiation that is related to their tumour-promoting 
effect(s) [24–25]. However the factors within the cancer 
cell secretome responsible for driving this particular 
differentiation programme remain incompletely 
understood. Some recent studies point to a potential role 
for small extracellular vesicles, called exosomes, which 
are secreted in relative abundance by cancer cells. Such 
vesicles are pre-manufactured within late endosomal 
compartments called multivesicular endosomes. These 
are transported to, and fuse with, the plasma membrane 
resulting in vesicle release into the extracellular space 
[26]. Regulators of exosome biogenesis and trafficking 
within cells are poorly understood but some Rab-
family members have been implicated in trafficking. 
Of these, Rab27a and Rab27b are the most extensively 
studied to date, as knockdown of these proteins offer a 
means of selectively inhibiting exosome secretion by 
various cell types [27]. Our recent studies showed cancer 
exosomes can act to modulate stromal cell fate, driving 
fibroblast to myofibroblast differentiation, in a manner 
requiring exosomally-tethered TGFβ1 [28], and that 
such myofibroblasts had potent angiogenic and tumour 
promoting properties in vivo; effects that were lost when 
using Rab27a knockdown cancer cells [29]. Exosomes 
from other cancer types may also impart similar effects on 
driving a myofibroblast-like differentiation process, and 
MSC of adipose or cord-blood origin have been reported 
to be responsive to exosomally delivered TGFβ1 [30–32].
In the current report, therefore, we examined the 
possible influence of prostate cancer derived exosomes 
on bone marrow derived MSC, and in turn the reciprocal 
influence of modified MSC on endothelial cells and tumour 
cells. We demonstrate exosomes play a role in controlling 
BM-MSC differentiation to myofibroblasts, through 
a TGFβ1 dependent mechanism, producing cells that 
exhibit heightened VEGF, HGF and metalloproteinases. 
Exosome-differentiated MSC in turn enhanced tumour 
and endothelial cell proliferation and migration, supported 
endothelial vessel formation and tumour invasion in vitro. 
Prostate cancer exosomes can therefore dictate the fate of 
MSC in a dominant manner, generating myofibroblastic 
cells with tumour promoting characteristics.
RESULTS
Characterisation of BM-MSC
We analysed the surface-phenotype of commercially 
obtained BM-MSC according to the classical ISCT 
criteria, comparing them to fibroblasts and myofibroblasts. 
Although the BM-MSC well satisfied the expected 
characteristics of positive expression for the markers 
CD146, CD90, CD104, CD44 and CD73 and negative 
for CD45 (not shown), the other types of stromal cells 
analysed also displayed these characteristics (Fig. 1A). 
This panel of markers alone cannot therefore distinguish 
MSC from fibroblasts, or from myofibroblasts generated 
by 72 h treatment of fibroblasts with soluble TGFβ1 (at 
1ng/ml). However, positive staining for the embryonic 
stem cell marker SSEA-4, and the Ganglioside GD2 
previously reported as MSC markers [33], was absent 
from other stromal cell types, demonstrating BM-MSC are 
phenotypically distinct from other stromal types.
We next examined the capacity of these cells 
to undergo a classical form of MSC-differentiation, 
namely into adipocytes. Following culture in appropriate 
conditions for a period of 21 days, BM-MSC developed 
multiple lipid droplets within the cytosol, stained intensely 
with Oil red O (Fig. 1B). Fibroblasts treated identically 
showed no signs of adipogenic differentiation.
Exosomes were purified from prostate cancer DU145 
cells and were previously shown to contain around 7pg of 
TGFβ1 per μg of exosomes [28, 34]. These were repeatedly 
added (at 150 μg/ml) to some wells together with adipogenic 
differentiation factors every 3 days throughout the 21 day 
experiment. This dose of exosomes is approximately 
equivalent to 1ng/ml of TGFβ1. Alternatively, soluble 
TGFβ1 (at 1ng/ml) was added instead of exosomes, 
and the effects on adipogenesis were compared. Either 
treatment resulted in significant (P < 0.001) inhibition of 
differentiation into adipocytes (Fig. 1C).
The data demonstrate that the BM-MSC used in 
the study were consistent with expectations of MSC 
phenotype and differentiation capacity, but crucially the 
differentiation fate of these cells can be modulated by 
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Figure 1: Characterisation of BM-MSC phenotype and differentiation. Commercially obtained BM-MSC (at passage 2) were 
analysed by flow cytometry for a range of markers as depicted. These cells were compared to fibroblasts or to myofibroblasts generated 
following 3d treatment of fibroblasts with sTGFβ (1ng/ml). Bars show median fluorescence intensities (MFI) of duplicate measurements 
(A). Culture of BM-MSC or fibroblasts under conditions favouring adipogenic differentiation for 21 days was followed by staining with 
Oil Red O (Scale, 100μm) (B). Selection from image showing clusters of Oil Red O-stained fat droplets in adipocytes (B, inset). During 
adipogenic differentiation, sTGFβ (1ng/ml) or prostate cancer exosomes (150 μg/ml) were repeatedly added and the formation of Oil Red O 
positive adipocytes examined at day 21. Bars show the mean (± SD) number of adipocytes per field of view, from a total of 10 microscopic 
fields examined in duplicate wells per treatment, and are representative of two independent experiments (C).
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cancer-derived exosomes which are capable of overriding 
the adipogenic differentiation programme.
Exosome treated BM-MSC become 
myofibroblast-like
We examined whether or not BM-MSC respond to 
exosomes by differentiating into a phenotype similar to 
that of cancer associated stromal cells as we described 
recently for the response of fibroblasts to exosomes 
[29]. Under adipogenic conditions, exosomes or sTGFβ 
were added during the 21-day differentiation period and 
the impact on expression of the myofibroblastic marker 
alpha-smooth muscle actin (αSMA) was examined. The 
proportion of αSMA positive cells remained low (<5%) 
under adipogenic differentiation conditions, and this was 
not altered following sTGFβ treatment. In contrast, more 
than 50% of the cells exhibited strong αSMA expression 
following treatment with exosomes at a matched TGFβ-
dose (Fig. 2A).
A simpler experiment was next performed in the 
absence of adipogenic differentiation conditions, giving 
a single stimulation with exosomes or sTGFβ at day 0, 
and evaluating the outcome earlier at day 14. Here again 
exosomes but not sTGFβ drove a significant elevation 
in αSMA positive cells (Fig. 2B), with the majority 
becoming positive for αSMA. Importantly αSMA protein 
was not simply elevated in these experiments but was 
present as organised stress-fibres (Fig. 2B); the onset 
of which is a key characteristic of myofibroblasts [35]. 
A single stimulus with exosomes was therefore sufficient 
to trigger myofibroblastic differentiation independently of 
any other differentiation factor. The response to exosome 
treatment was dose dependent, with an approximately 3 
fold elevation, to ~30% of the population becoming αSMA 
positive at 75 μg/ml. This increased to around 75% with 
very high exosome doses of 300 μg/ml (Fig. 2C, and 
Fig. S1). The kinetics of αSMA onset however, was slower 
than we expected, certainly slower than that for fibroblasts 
in which αSMA peaks at around 72 h post exosome-
stimulation [28]. There was no change in αSMA status by 
72 h for BM-MSC, with changes only becoming apparent 
6 days post exosome treatment but continuing steadily 
thereafter approaching 70% positivity by day 14 (Fig. 2D, 
Fig. S2).
Because the response of fibroblasts to exosomes 
is principally dependent on exosomal-TGFβ [28], we 
investigated the impact of interfering with TGFβ signalling 
using either an inhibitor of the Alk5 TGFβ-receptor-I 
(SB431542) or using a neutralising antibody against 
TGFβ that will bind to and inhibit exosomally-delivered 
TGFβ1 as we described [28–29]. Exosomes added with 
either inhibitor failed to trigger differentiation into αSMA-
positive cells (Fig. 2E). The mechanism of action therefore 
requires exosomal-TGFβ driving signalling through 
TGFβ-receptor-I, yet this myofibroblastic phenotype 
cannot be reproduced using a matched dose of sTGFβ 
(Fig. 2A, 2B).
By adding purified exosomes to BM-MSC, however, 
it is difficult to evaluate if this effect is an artificial 
artefact due to the nature of the doses we have studied. 
We therefore investigated the role of exosomes naturally 
present within the cancer cell secretome by adding cancer 
cell conditioned media, normalised for cell number, to 
BM-MSC. For these experiments we used cancer cells 
that had been rendered deficient in exosome secretion by 
knockdown of Rab27a as described [27, 29]. Alternatively, 
we simply depleted exosomes from the conditioned 
media using ultracentrifugation. In the absence of such 
manipulations cancer cell conditioned media was capable 
of driving the differentiation of BM-MSC into αSMA-
positive myofibroblasts (Fig. 2F). This was strongly 
inhibited when using cell medium from exosome deficient 
Rab27aKD cells or when depleting the cell medium of 
exosomes by ultracentrifugation. With respect to the 
latter, the exosome-containing pellet resuspended in the 
original volume of medium was sufficient to fully restore 
differentiation. We conclude that exosomes and not other 
soluble factors within the cancer cell secretome are chiefly 
responsible for controlling the differentiation of BM-MSC 
into myofibroblasts.
Exosome treated BM-MSC elevate pro-angiogenic 
factors and metalloproteinase’s
Because cancer associated stroma are implicated in 
supporting angiogenesis [29], we examined the possible 
effects of exosome-driven differentiation on angiogenic 
factors VEGF-A and HGF. A single stimulus with either 
exosomes or sTGFβ1 was given and an ELISA was used 
to measure the contents of BM-MSC conditioned media 
at several time points thereafter. There was a clear cut 
stimulation of VEGF secretion following exosome-
treatment, which was more than 3-fold baseline levels 
after only 4 days, peaking at 8 days but still remaining 
elevated for the 2 week experiment (Fig. 3A, left). The 
levels here were far in excess of the VEGF-A added 
to the system in association with Du145-exosomes 
which we previously measured at 3pg VEGF-A per 
1 μg of exosomes, giving 450pg/ml of VEGF-A added 
to the system [36]. Stimulating with sTGFβ had no 
impact on VEGF levels. There was a spontaneous rise 
in HGF levels from untreated BM-MSC, but this was 
still heightened following exosome treatment. Of note, 
sTGFβ treatment inhibited the spontaneous secretion of 
HGF (Fig. 3A, right), a phenomenon we also reported 
for fibroblasts [29]. Exosome stimulation therefore 
supports the production of pro-angiogenic proteins, and 
these alterations occur before the full onset of the αSMA-
positive phenotype.
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Figure 2: Exosomes drive differentiation of BM-MSC to a myofibroblast-like phenotype. Under adipogenic conditions, 
exosomes (150 μg/ml) or sTGFβ (1ng/ml) were added to BM-MSC, as depicted and at 21 days the cells were stained for αSMA (green) and 
DAPI (blue). Quantitation of the proportion of αSMA positive cells, from a total of 6 microscopic fields examined in duplicate wells per 
treatment, is shown. Representative of two independent experiments (A). A single treatment with exosomes or sTGFβ, at the above dose, 
in the absence of adipogenic differentiation factors was performed, and at day 14 cells were stained and quantified for αSMA positive cells 
as above. Representative of 5 such experiments (B). BM-MSC were stimulated for 14 d with increasing doses of exosomes (0–300 μg/ml), 
and the proportion of αSMA positive cells were counted as above (C). Similarly at a fixed dose of exosomes (150 μg/ml), the proportion 
of αSMA actin positive cells were determined at time points up to 14 days (D). BM-MSC were treated with exosomes (150 μg/ml) in the 
absence or presence of the Alk-5 inhibitor (SB431542) or neutralising antibody against TGFβ, and at day 14, αSMA expression quantified 
as above (E). Culture medium normalised for cell number, was taken from control or Rab27aKD Du145 cancer cells, or from control 
Du145 cells following ultracentrifugation to pellet exosomes (120,000g supernatant), or the exosome-containing pellet from this spin was 
resuspended in the original volume and used (120,00g pellet). These CM were added to BM-MSC and at day 14 αSMA expression was 
quantified as above, representative of two experiments.  (Continued )
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Figure 3: Phenotypic changes in exosome-differentiated BM-MSCs. Conditioned media taken from BM-MSC treated with 
exosomes (150 μg/ml) or sTGFβ1 (1ng/ml) at specified time points, were analysed by ELISA for levels of VEGF (left) or HGF(right) (A). 
Volcano plot, depicting results from RT2-Profiler™ fibrosis array comparing day4 untreated BM-MSC with exosome-treated MSC (B, left) 
or with sTGFβ treated exosomes (B, middle) or exosome-treatment vs sTGFβ treatment (B, right). Applied thresholds were a fold change 
of ± 3 and a p-value of ≤0.05 (t-test based on biological triplicates per treatment) (B). TaqMan-PCR verification of selected transcripts 
identified by the array, revealing reproducible and significant changes in relative mRNA with GAPDH as an internal standard, at day 4. 
Columns represent Log2(relative expression) ± SD, compared to untreated BM-MSC (based on biological triplicates) (C).
Figure 2: (Continued ) Exosomes drive differentiation of BM-MSC to a myofibroblast-like phenotype. (F) (Scale, 
100 μm, Bars, Mean ± SD).
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Due to these results, we also explored more broadly 
the consequence of exosome-stimulation on the BM-MSC 
phenotype arising. Using a focussed PCR-array method, 
with coverage of 84 transcripts of known involvement 
in tissue scarring/fibrosis-like reactions (Supp Table S1), 
we examined differential mRNA expression among the 
BM-MSC treated with exosomes or sTGFβ. Treatment 
with sTGFβ was not inert, as we saw elevated mRNA for 
IL-1A and INHBE, whilst there was a decrease in 
SMAD3, SMAD6, CCL2, IL5, ITGB8 and HGF compared 
to untreated BM-MSC (Fig. 3B, blue circles). Treatment 
with exosomes also elevated INHBE and IL1A, whilst 
decreasing ITGB8, but otherwise the alterations were 
dissimilar to those mediated by sTGFβ. Exosomes strongly 
elevated MMP-3, MMP-13, and SerpinA1 and less 
strongly ITGA2, ITGB6 and MMP1 compared to untreated 
BM-MSC (Fig. 3B, red circles). Exosome treatment also 
triggered a decrease in AGT and BCL2. Those transcripts 
that could discriminate exosomes from sTGFβ stimulation 
are shown (Fig. 3B, right, green circles), and include HGF, 
IL5, CCL2, TGFB3 in addition to the metalloproteinase’s. 
Whilst there was an elevation in mRNA for VEGFA with 
exosome stimulation, the changes were below our chosen 
threshold for consideration as differentially expressed 
(<3x fold change). In independent experiments, qRT-PCR 
was used to confirm exosome mediated changes in the 
transcripts demonstrating particularly strong (160-fold) 
elevation in MMP-3 and also elevated MMP-1, MMP-13, 
and SerpinA1, with decreased mRNA for AGT, showing 
broad agreement with the array data (Fig. 3C). The levels 
of these transcripts present in RNA isolated from DU145-
exosomes were negligible, and therefore do not account 
for the observed changes (Fig. S3). Together the array 
shows that exosomes impart a phenotype that has some 
overlap with that of sTGFβ stimulus, but points to some 
unique features including heightened HGF and matrix 
regulating proteases such as MMP’s.
Exosome generated myofibroblasts exhibit  
pro-angiogenic functions
We next explored some possible functional aspects 
of exosome-differentiated BM-MSC, examining whether 
or not exosome-mediated differentiation gives pro-
angiogenic function. To do this we investigated several 
aspects of endothelial cell behaviour in vitro.
Firstly we examined the proliferation and survival 
properties of umbilical vein-derived endothelial cells 
(HUVEC) in the presence of BM-MSC conditioned 
medium (CM), collected from BM-MSC pre-treated for 
4d with exosomes or sTGFβ. The CM was added in the 
absence of exogenous endothelial-cell growth factors, and 
at day 6, cell viability and cell numbers were determined 
by flow cytometry. The viability of endothelial cells grown 
in BM-MSC conditioned medium was >75%, but there 
was a small increase using CM from either sTGFβ or 
exosome-treated BM-MSC. The endothelial cell numbers 
expanded poorly with CM from untreated BM-MSC, 
and there was a weak proliferative response to CM from 
sTGFβ treated BM-MSC. This was slightly stronger, 
however following exosome treatment of BM-MSC and 
lead to a 3-fold elevation of endothelial cell numbers 
at day 6. Exosome-differentiated BM-MSC, therefore, 
produce factors which support endothelial cell expansion 
(Fig. 4A).
We also examined the influence of BM-MSC on 
endothelial cell migration using an endothelial monolayer 
scratch assay. Conditioned media, from exosome-treated 
BM-MSC, accelerated scratch closure, with full closure 
of the scratch occurring by 24 h. In contrast the scratch 
exposed to sTGFβ-treated BM-MSC conditioned medium 
was only 50% closed by 24 h (Fig. 4b). At this time point, 
the endothelial cells were alive but poorly adherent in 
the presence of CM from untreated BM-MSC, and as 
such it was not possible to determine the position of the 
scratch margins at 24 h. Nevertheless, scratch closure 
for this treatment was clearly less complete at 6 and 
18 hr compared to the other treatments (Fig. 4B), and 
this phenomenon was apparent in three independent 
experiments.
Lastly, we performed an in vitro tubule-formation 
assay as a measure of proliferation, migration and cell 
organisation, through co-culture of pre-treated BM-MSC 
monolayers with endothelial cells, as described [37]. BM-
MSC were treated with exosomes or sTGFβ for 4 days 
prior to the drop-wise and scattered addition of endothelial 
cells to the wells. After a further 6 days cells were fixed 
and stained for the endothelial marker CD31. In wells 
containing untreated BM-MSC some clusters of CD31-
positive cells formed on top of the BM-MSC monolayer, 
but these were relatively rare, forming short structures with 
no evidence of branching. In contrast, exosome-treatment 
of BM-MSC allowed the support of multiple branched, 
long and wide structures consistent with supporting 
more elaborate vessel-like structures [38]. There was a 
significant elevation in the total surface area occupied by 
CD31-positive cells (Fig. 4C). Stimulating BM-MSC with 
sTGFβ failed to generate such structures, instead generated 
structures similar to those seen for untreated BM-MSC. In 
summary, exosome-differentiated BM-MSC support the 
proliferation, motility and organisation of endothelial cells 
and are consistent with a pro-angiogenic function.
Exosome generated myofibroblasts support 
tumour cell expansion, migration and invasion
Cancer associated stroma may also be considered 
as a direct stimulus for tumour growth; we therefore 
examined the impact of exosome-generated myofibroblasts 
on Du145 prostate cancer cells.
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CM was taken from 4 day differentially treated 
BM-MSC and added to tumour cells for 3 days prior to 
assessment of cell number and viability by flow cytometry. 
CM taken from either sTGFβ or exosomes stimulated BM-
MSC exhibited a pro-proliferative effect, with cell number 
increased 6 to 7 fold after 3 days, compared to CM from 
untreated BM-MSC (Fig. 5A). There was also an increase 
in cell viability with these treatments, consistent therefore 
with direct MSC-support of tumour cell expansion. These 
effects were not due to carry-over of cancer exosomes 
within the MSC CM as these controls showed no such 
activity (not shown) pointing to MSC-derived factors as 
essential.
We also used a monolayer scratch assay, to examine 
tumour cell motility in response to the same CM. Scratch 
closure following treatment with CM from sTGFβ -BM-
MSC was not different from untreated control, with closure 
at ~70% after 10 hr. There was, however, a significant 
Figure 4: Pro-angiogenic functions of exosome-differentiated BM-MSC. Conditioned media from BM-MSC pre-treated for 
4 days as specified, was added to wells containing 1 x 104 primary HUVEC. Following 6 days in culture, HUVEC were harvested and 
viability and cell counts performed using the ViaCount system on a Guava flow cytometer (Bars, mean ± SD, of triplicates) (A). Confluent 
monolayers of HUVEC were established, prior to scrapping a single vertical scratch using a 200μl pipette tip. CM from BM-MSC pre-
treated as specified, were added, and the distance between two sides of the scratch, highlighted by vertical white lines and arrows, was 
monitored at specified time points microscopically up to 24 h. The symbol † depicts a loss of HUVEC adhesion at 24 h, hence scratch width 
could not be measured. (Graph shows Mean ± SD, of duplicate wells per treatment. Data are representative of two such experiments (B). 
Monolayers of BM-MSC were pre-treated as specified for 4 days, at which point 50% of the culture medium was removed, and replaced by 
the same volume of EBM2 endothelial cell culture medium lacking growth factors, containing 20,000 HUVEC per well. After further 6 day 
incubation, the co-cultures were fixed and immune-fluorescently stained for CD31 (green) and DAPI (blue) (Scale, 100μm). Quantification 
of surface area of the CD31-positive structures was performed (Bars, Mean ± SD of triplicate wells per condition). Representative of three 
such experiments (C).
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Figure 5: Tumour-growth promoting functions of exosome-differentiated BM-MSC. Conditioned media from BM-MSC 
pre-treated for 4 days as specified, was added to wells containing 1x104 DU145 tumour cells that had been grown under serum-free 
conditions for 24 h previously. Following 3 days in culture, Du145 cells were harvested and viability and cell counts performed using 
the ViaCount system on a Guava flow cytometer (Bars, mean ± SD, of triplicates) (A). Confluent monolayers of Du145 tumour cells 
were subject to a single vertical scratch, and CM from pre-treated BM-MSC was added. The distance between the scratch margins was 
measured at time points up to 24 h. (Bars, Mean ± SD, duplicate wells) (B). Spheroid cultures were established in poly-haema coated plates, 
composed of Du145 cells (control or Rab27KD), or a combination of Du145 cells with BM-MSC (at a ratio of 4:1 respectively), at 104 
total cells/spheroid. After 4 days when cells had formed firm spheroid structures, they were transferred to fresh wells and Matrigel™ was 
added. The area occupied by extra-spheroidal cell outgrowths was measured daily for up to 96 hr. For late time-points, multiple images of 
the spheroid-outgrowths were taken and these were tiled to form a composite representation of the full extent of outgrowth. (Graph shows 
Mean ± SD, quadruplicate spheroids per treatment) (C). In order to obtain enough RNA, 5 such spheroids were pooled) and total RNA was 
extracted and evaluated for levels of MMP-3 mRNA. Columns represent Log2(relative expression) ±SD, compared to untreated control 
tumour only (based on technical triplicates) (D).
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(p < 0.001) increase in scratch closure when using CM 
from exosome treated BM-MSC, with 95% closure at the 
same time point (Fig. 5B). Exosome-treated BM-MSC 
therefore produce factors that enhance tumour cell motility.
We also established 3D-spheroid cultures, 
incorporating either tumour cells alone or tumour cells 
with BM-MSC (at a ratio of 4 tumour cells to 1 BM-
MSC), in order to mimic an in vivo 3D microenvironment. 
In these experiments we used the aforementioned exosome 
deficient tumour cells (Rab27aKD), and the respective 
vector control cells. After establishing spheroids for 
four days, spheroids were transferred to fresh wells 
and Matrigel™ was added burying the spheroids in 
a 3D basement-membrane mimic. Each well was 
microscopically examined for 96 hours, to ascertain 
whether or not there was any effect on escape of cells out 
from the spheroid into the surrounding matrix. Control 
or Rab27aKD tumour cells alone showed a paucity of 
cell outgrowth even at 96 hours (Fig. 5C). In marked 
contrast, combining BM-MSC with control tumour 
cells revealed notable outgrowth as early as 24 hours 
(Fig. S3), and growing beyond the field of view of the 
objective at 48 hours. By tiling multiple images we were 
able to continue to assess invasion for up to 96 hours 
demonstrating a highly significant increase in the area 
occupied by extra-spheroidal cells (p < 0.0001) (Fig. 5C, 
graph). In contrast, exosome deficient tumour cells 
together with BM-MSC invaded the matrix somewhat 
later at 48 hours (Fig. S4), and this was drastically less 
extensive by 96 hours (Fig. 5C), with a clear attenuation 
of invasive capacity in the absence of an intact exosome 
secretion pathway. As MMP-3 was highly elevated 
(>100 fold) in BM-MSC in the presence of exosomes 
(Fig. 3C) we extracted RNA from a pool of 5 spheroids 
per treatment group and examined possible alterations 
in this transcript within the spheroids. The same pattern 
was apparent here also, with heightened MMP-3 mRNA 
found only in the presence of BM-MSC together with 
control tumour cells (Fig. 5D). Omission of BM-MSC or 
using Rab27a silenced tumour cells did not show MMP-3 
elevation. Therefore exosome-mediated MMP-3 induction 
in BM-MSC correlates with a pro-invasive function.
In summary, exosome-differentiated BM-MSC 
directly promote tumour proliferation and motility. 
Assistance from BM-MSC is required to trigger the 
matrix invasion characteristics of the 3D-spheroid model, 
and inhibiting exosome secretion here strongly attenuates 
tumour invasion.
DISCUSSION
The cross-talk between cancer cells and local 
stromal cells has seen renewed interest in recent years, 
with mounting evidence for a profound influence of 
fibroblastic stroma in driving disease progression and poor 
clinical outcome [8, 39]. Several studies have identified 
common characteristics of cancer associated stromal cells 
across diverse solid cancer types. These include molecular 
traits of myofibroblasts, which promote tumour cell 
growth directly and stimulate angiogenesis [11, 40–41]. 
However, some recent reports in pancreatic carcinoma 
where myofibroblasts are conditionally ablated by genetic 
means at different time points during carcinogenesis, 
reveal heightened angiogenesis and immune-suppression 
following removal of myofibroblasts, with worsening 
overall survival of mice [42–43]. Such studies suggest 
that in this model at least, stromal myofibroblasts 
play a protective role in attenuating the disease [43]. 
Whilst currently such data is lacking for other cancer 
types, the prevailing paradigm views cancer-associated 
myofibroblasts as prognostically poor. There remains 
however, incomplete understanding about stroma, its 
cellular and molecular nature and its consequence in terms 
of disease outcome.
Precisely how myofibroblastic traits of cancer 
associated stroma are initiated; altering stroma from 
a normal homeostatic function towards a malevolent 
or indeed a protective phenotype remains unclear. 
Although TGFβ secreted by cancer cells has remained 
among the principal culprits driving myofibroblastic 
differentiation, studies by us [28–29] and others 
[30–32, 44] have recently highlighted a role for exosome 
vesicles in delivering TGFβ to elicit stromal modulation 
in cancer. Local tissue fibroblasts exhibit the capacity to 
differentiate into myofibroblasts under the influence of 
soluble TGFβ, and this requires additional factors such as 
endogenous hyaluronic acid production and the interaction 
between CD44 and the EGF receptor [45]. The detailed 
myofibroblastic phenotype arising however appears to 
differ from cancer associated stromal cells, as it is not 
pro-angiogenic, and fails to enhance tumour growth in 
xenografts [29]. In contrast, stimulating the same stromal 
cell source with TGFβ-bearing prostate cancer exosomes 
generates myofibroblasts that mimic those extracted from 
cancerous tissues; driving angiogenesis and in vivo tumour 
promotion [29]. The onset of αSMA stress fibres in stromal 
cells is not therefore directly coupled to their tumour-
modulating function; and a better surrogate indicator 
of stromal functionality may be the secretion of certain 
factors including SDF-1 [24], VEGF and HGF [29].
In our presented study, TGFβ-bearing prostate cancer 
exosomes modulated the differentiation of BM-MSC, giving 
rise to a myofibroblastic phenotype exhibiting heightened 
VEGF and HGF secretion. The cell arising, therefore 
represent those aforementioned traits of cancer associated 
stroma even though the originating cell source is distinct. This 
suggests that it is the nature of the trigger (i.e. exosomes), 
rather than the originating cell type, that is most important 
for the function of the myofibroblast arising. In contrast, 
soluble TGFβ stimulation of BM-MSC gave a radically 
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different response that lacked onset of αSMA-stress fibres 
or elevated VEGF, and reduced constitutive HGF secretion. 
With different sources of both cancer exosomes and MSC, 
other studies have also described exosome-mediated 
myofibroblastic differentiation of adipose tissue or umbilical 
cord blood-derived MSC [30–31, 44] and show the role of 
TGFβ, and SMAD-dependent signalling in this process. 
Comparing directly, however, the effects of exosomes and 
sTGFβ, as we have done highlights the profound difference 
in the cell response arising, with the exosomal-form of 
TGFβ giving a clearly distinctive molecular and functional 
phenotype. A detailed mechanistic explanation for this 
difference is currently lacking, and given the molecular 
complexity of exosomes secreted by cancer cells, represents 
a significant challenge to define. Certainly for fibroblast 
stimulation by exosomes, we revealed that intact heparan 
sulphate proteoglycans at the exosome surface were required 
for functional delivery of vesicular TGFβ [29]. The possible 
co-delivery of other factors such as growth factors, or 
vesicular mRNA or miRNA are aspects we are currently 
examining. What is clear is the exosome-mediated generation 
of myofibroblasts from BM-MSC is a TGFβ-dependent 
process which produces a phenotype with the expected 
characteristics of cancer associated stromal cells.
We have not yet addressed the nature of the MSC 
response to exosome stimulation in terms of the cell 
population, and are currently unclear as to whether the 
response is homogenous, or whether it is a sub-population 
of MSC which differentiate into myofibroblasts that 
subsequently proliferate to take over the population. We 
present evidence that around 60–70% of MSC exhibit 
αSMA positivity after around 2 weeks which is quite 
different from stimulating fibroblasts where essentially 
~100% of cells become positive by 3 days [28]. Such 
observations suggest a more heterogeneous response 
with MSC as a stromal cell source. The question may 
have in vivo relevance, as the infiltration of the cancer 
microenvironment by few MSC may be sufficient to 
generate an expanding population of myofibroblastic cells 
in situ. We are currently addressing such questions to gain 
greater insight into such exosome-mediated changes in 
subpopulations of stem cells.
The functional properties of the exosome-generated 
myofibroblasts support the premise that cancer exosomes 
have a disease-promoting influence. Although the direct 
impact of cancer exosomes on angiogenesis has been 
well documented [37, 46], the impact of exosome-
modified BM-MSC on this process has not to our 
knowledge been studied. Endothelial cells exhibited 
preferential proliferation and migration in the presence 
of soluble factors produced by exosome-differentiated 
BM-MSC. We also document an enhanced capacity to 
form complex vessel-like structures. These were akin 
to structures produced using natural, cancer-tissue 
derived stromal cells of prostate origin [29]. In a similar 
fashion, we show a direct positive effect of exosome-
generated myofibroblasts on tumour cell proliferation 
and motility, but moreover a heightened propensity to 
invade into extracellular matrix using a 3D spheroid 
model. Extensive invasion was abrogated when targeting 
exosome secretion by Rab27a silencing, and invasion 
was absent when BM-MSC were left out of the spheroids 
highlighting the role of this stromal cell type in dictating 
invasive behaviour. We do not know whether the 
invading cells are principally epithelial or mesenchymal 
in nature, but given the predominance of tumour cells 
(4:1) in the spheroids, and the pro-proliferative influence 
of BM-MSC on tumour cells, the invading cells are most 
likely to be principally epithelial as their morphology 
would suggest. This high invasive capacity of the system 
agrees with additional evidence showing exosome-driven 
metalloproteinase elevation in BM-MSC, an aspect 
peculiar to exosome-stimulus and not found when using 
sTGFβ1. Such factors, which include the collagenases 
MMP-1 and MMP-13 and the stromelysin MMP-3, have 
well documented roles in disease progression and can 
in particular aid cell penetration through extracellular 
matrices, supporting invasion and metastasis in several 
cancer types [47]. Notably a recent study highlighted 
bone-marrow derived myofibroblasts found at the primary 
tumour site in a skin cancer model as the principal source 
of MMP-13 in situ [48], and that this MMP was required 
for subsequent invasive behaviour [48–49]. Furthermore, 
a recent study has demonstrated that down-regulation of 
MMP-3 in cancer-associated fibroblasts subsequently 
attenuated prostate cancer cell invasion [50]. In addition 
a novel role for proteases in association with stromal-cell 
derived exosomes appears to be an important element 
in controlling stromal cell phenotype and subsequent 
microenvironmental changes. Stromal exosomes taken 
from cells deficient in TIMPs, harbour bioactive enzymes 
such as ADAM10 that support the generation of 
myofibroblasts with classical traits of tumour promotion 
including heightened HGF, SDF1 and other factors [51]. 
Whether exosomes of differentiated MSC exhibit such 
proteolytic activities and functions are not currently 
known. Other transcripts modulated by exosomes 
were ITGB6 and ITGB8 encoding for components 
of the integrin αvβ6 and αvβ8 respectively, which are 
implicated in the conversion of latent-TGFβ to bioactive 
TGFβ in several systems [52–53]. The importance of 
these exosome-mediated integrin changes in BM-MSC 
for TGFβ activation and adhesive functions has not yet 
been investigated but certainly deserves future attention. 
The functional data in relation to spheroids and to the 
pro-angiogenic properties of differentiated BM-MSC 
correlate well with the phenotypic alterations induced 
by exosome stimulation. These changes emphasise the 
profound role of MSC-cooperation with tumour cells in 
driving distinct aspects of disease progression, and the 
Oncotarget12www.impactjournals.com/oncotarget
requirement for a functional cancer exosome secretion 
pathway for this influence to be fully realised.
We acknowledge that the specificity of the Rab27a 
silencing approach for inhibiting the secretion of exosomes 
and not other factors is somewhat controversial [54], 
and we are cautions about over reliance on this as a sole 
means of showing a role for exosomes. Soluble cancer-
cell derived factors have been shown through prolonged 
exposure to mediate myofibroblastic differentiation 
of MSC [24], and we clarify through some simple 
experiments that exosomes are the dominant factor in 
this process. Reducing the level of exosomes in cancer 
cell conditioned media, by high speed centrifugation, 
generated cell conditioned media that was poor in driving 
myofibroblast differentiation. The activity resides in 
the 120,000xg pelletable fraction, strongly implicating 
exosomes as mechanistically central to cancer-mediated 
control of MSC. In addition, the use of purified exosomes 
and the Rab27a silencing approach collectively provide 
data supporting these conclusions.
MSC exhibit enormous cellular plasticity, capable 
of a broad range of differentiation programmes. These 
are complex to demonstrate in vitro however, requiring 
assorted hormonal or growth factor stimulations applied 
sequentially often over long time periods. For tissue 
engineering applications, optimising and simplifying 
such protocols remains a major biotechnological 
challenge in the context of cellular therapeutics. Here 
we have only explored adipogenic differentiation as one 
of the classical differentiation routes for BM-MSC. The 
addition of TGFβ-positive exosomes during this form of 
differentiation was sufficient to block and fully override 
the formation of adipocytes to preferentially generate 
myofibroblasts. What is equally remarkable is that a single 
stimulation with exosomes was sufficient to trigger the 
onset of αSMA-positive cells over the course of 2 weeks. 
This opens novel exploratory avenues for manipulating 
MSC differentiation using various exosome sources to 
dictate the desired differentiation programme. Although 
supporting evidence is currently lacking, our data suggest 
cancer exosomes may be capable of overriding the natural 
control of MSC differentiation in vivo, away from a self-
renewal or reparative phenotype towards undesirable 
disease promoting myofibroblasts.
We do not currently know if such exosomes are 
capable of distant communication from the primary site 
of prostate, to bone marrow. In other systems, melanoma 
exosomes have documented roles in mobilising bone-
marrow haematopoietic and non- haematopoietic 
progenitors which in turn influence disease progression 
[55]. The role of prostate cancer exosomes in mobilising 
BM-MSC remains an open question of considerable 
interest.
In conclusion, our report identifies prostate 
cancer exosomes as potent factors for controlling the 
phenotypic and functional differentiation of BM-MSC 
towards a pro-angiogenic and pro-invasive myofibroblast. 
The phenotype is similar to that reported for cancer 
associated stromal cells, with exosomes and not other 
soluble factors required to generate this dominant form 
of differentiation. We therefore advocate that molecular 
targeting of this exosome-driven process in a clinical 
setting is likely to attenuate tumour-manipulation of the 
local microenvironment, and slow disease progression.
MATERIALS AND METHODS
Cell culture
The prostate cancer Du145 [56] cell line was 
purchased from ATCC, and used for all the experiments 
shown. Some confirmatory experiments in relation to 
exosome driven MSC-differentiation were also performed 
using the PC3 prostate cancer cell line (also from ATCC), 
with similar effects (not shown). The cells were seeded 
into bioreactor flasks (Integra, Nottingham, UK), and 
maintained at high density culture for exosome production, 
as previously described [57]. The cells were cultured in 
RPMI 1640 (Lonza, Wokingham, UK), supplemented 
with penicillin/streptomycin and 10% foetal bovine serum 
(FBS; Life Technologies, Paisley, UK). FBS was depleted 
of bovine exosomes by overnight ultracentrifugation at 
100,000 g, followed by filtration through 0.2 μm and then 
0.1 μm vacuum filters, (Millipore, Hertfordshire, UK). For 
some experiments Du145 rendered deficient in Rab27a 
using a ribozyme knockdown method, were used [29]. 
Human bone marrow MSC were purchased from Promocell 
(Heidelberg, Germany). And expanded according to the 
suppliers instructions using Promocell culture media, with 
supplement mixture. For MSC-differentiation experiments 
the culture medium was DMEM-low glucose (1 g/l) 
(Lonza) with 10% MSC-optimised FBS (also rendered 
exosome depleted as above). All experiments were 
conducted with early passage MSC (up to passage 5). Cells 
were confirmed negative for mycoplasma contamination 
by monthly screening (MycoAlert; Lonza). Adult lung 
fibroblasts (Coriell Institute for Medical Research, USA) 
were maintained in DMEM/F12 (Lonza) and 10% exosome 
depleted FBS. Human umbilical vein endothelial cells 
(HUVEC) were purchased from Lonza, and maintained 
using the EBM2-bullet kit. For functional assays, these 
additional growth factor supplements were withdrawn for 
the duration of the experiments.
Exosome purification
Prostate cancer cell conditioned media (CM) was 
subjected to serial centrifugation to remove cells (400 g, 10 
min) and cellular debris (2000 g, 15 min). The supernatant 
was then filtered (0.22 μm), to remove remaining debris 
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and larger vesicles. The clarified CM was under laid with 
a 4ml cushion of 30% Sucrose/ D2O, and following 2 h 
ultracentrifugation at 100,000g (in a SW32 rotor, Beckman 
Coulter), the cushion was collected, and washed in excess 
PBS by ultracentrifugation. The pellet was resuspended 
in 50–100μl PBS and frozen in aliquots at -80oC. Unless 
stated otherwise, purified exosomes were used in assays at 
a dose of 150 μg/ml which is equivalent to a TGFβ dose 
of 1ng/ml [34]. Protein concentrations were evaluated 
using a microBCA protein assay (Pierce/Thermo, 
Northumberland, UK), and specified exosome doses used 
in experiments are based on this. The nano-particles in 
each preparation were quantified by nanoparticle tracking 
analysis (Nanosight, Malvern Instruments, Amesbury, 
UK) as described [58]. Preparations used for the study 
exhibited a particle : protein ratio of 2 x 1010 or greater, 
and were therefore considered high purity [58], and satisfy 
the size, density, structure and molecular phenotype of 
exosome vesicles as described [29]. To deplete exosomes 
from CM, samples were ultracentrifuged for 1.5 hr at 
120,000g (in a TLA110 rotor, Optima-Max Ultracentrfuge; 
Beckman Coulter, High Wycombe, UK), after which the 
supernatants contain ~90% fewer nano-particles measured 
by nanoparticle tracking analysis (Nanosight, Malvern 
Instruments, Amesbury, UK) (not shown).
Flow cytometry
BM-MSC, fibroblasts or myofibroblasts were 
harvested using acutase, and incubated on ice for 1 h 
with directly conjugated antibodies including; SSEA-
4-FITC (R&D Systems), CD44-PE (BD Bioscience), 
CD90-PE, CD105-APC, CD14-APC, CD45-PECy5 
(eBioscience, Hatfield, UK), CD73-PE (BD Biosciences, 
Oxford, UK). Indirect staining was performed for GD2 
(BD Biosciences), with a secondary goat anti-mouse-
Alexa488 conjugated antibody at 1:200 for 40 min (Life 
Technologies). Cells were analysed using a FACScanto 
cytometer (Beckton Dickinson, Oxford, UK), and data 
analysed using FACS Diva (v6.2).
Adipogenic differentiation
BM-MSC or lung fibroblasts were cultured in 24 
well plates and once confluent were given adipogenic 
induction medium (DMEM containing insulin, 
dexamethasone, indomycine and IBMX) as described [59]. 
In addition soluble recombinant human TGFβ1 (1ng/ml) 
or DU145 exosomes (150 μg/ml) was added along with 
the induction medium to some wells. Fresh adipogenic 
induction medium was given every 2–3 days over a period 
of 21 days, with the exception of day 7 and day 15, in 
which maintenance medium (DMEM with only insulin 
and FBS) was given. After 21 days of differentiation, 
adipocytes were fixed in 4% (w/v) paraformaldehyde 
and lipid droplets stained with Oil Red O Solution and 
counterstained with haematoxylin solution (Millipore).
Immuno-fluorescence microscopy
BM-MSC were cultured in growth factor free 
conditions for 24 h hours before stimulation with exosomes 
or sTGFβ at specified doses and times. In some experiments 
this was done in the presence of a neutralising TGFβ-
antibody at 10 μg/ml (R&D Systems, Abingdon, UK), or 
an inhibitor of the Alk-5 TGFβ-receptor-I (SB43152) at 
10 μm (Sigma-Aldrich, Dorset, UK). Cells were gently 
washed 3x in pre-warmed PBS. Cells were fixed in fresh, 
ice-cold acetone:methanol (1:1 v/v), for 5 min and allowed 
to completely dry in air at room temperature. Cells were 
blocked for 1.5 h in 1% BSA/PBS (w/v) protease free 
(R&D Systems). Anti α-smooth muscle actin (Santa Cruz 
Biotecnology, Santa Cruz, CA, USA) was used at 1 μg/ml 
(in 0.1% BSA/PBS w/v) for 1 h, and counterstained with 
DAPI for 10 min before washing 4 times in PBS. Cells 
were visualised by wide-field fluorescence (AxioVert, 
Zeiss, Cambridge, UK), and the proportion of αSMA-
positive cells was manually counted across 6 microscopic 
fields, and triplicate treatments unless stated otherwise.
ELISA
The quantity of VEGF-A or HGF present in the 
cell conditioned media of BM-MSC was assayed using 
the DuoSet ELISA system (R&D Systems) according 
to manufacturer’s instructions, except for the detection 
stage where the coluorimetric HRP-based detection 
was substituted for streptavidin-conjugated Europium 
(PerkinElmer, Cambridge, UK), and time resolved 
fluorimetry performed on a Wallac Victor2 (PerkinElmer).
PCR-arrays
To identify potential differences in the phenotype 
of differentiated MCS following exosome or sTGFβ 
treatment, cellular RNA was extracted at day 3 using 
Tri-Reagent (Sigma-Aldrich) as per the manufacturer’s 
protocol. Total RNA (0.5 μg) was reverse transcribed 
(RT2 First Strand Kit; Qiagen, Manchester, UK), prior 
to amplification using a low density PCR array (RT2 
Profiler PCR Array; Qiagen) covering 84 transcripts of 
known association with fibrosis. This was completed 
in accordance to the manufacturer’s instructions, and 
performed as biological triplicates for each treatment 
condition (9 arrays in total). The comparative Ct method 
was used for relative transcript quantification against 
the average ΔCt derived from internal controls (β-actin, 
β-2-microglobulin, GAPDH, HPRT1, and RPLP0). 
Data were analysed using the supplied software, and 
presented as volcano plots with a p-value threshold 
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of <0.05 and a fold-change threshold of ±3. Selected 
transcripts were verified using TaqMan PCR gene 
expression assays (Life Technologies), as described 
[28]. Target gene expression was quantified, using the 
comparative Ct method, relative to that of a standard 
reference gene (GAPDH). All PCR amplifications were 
performed in a StepOne Plus Real-Time PCR System 
thermocycler (Life Technologies).
Functional assays
Prior to functional assessments, endothelial cells 
or Du145 tumour cells were cultured for 24 h in growth-
factor free conditions prior to stimulations. BM-MSC 
were pre-treated for 4d with exosomes (150 μg/ml) or 
sTGFβ1 (1ng/ml) and conditioned media was harvested. 
BM-MSC was added to endothelial cells at a ratio of 
1:1 (v/v) with EBM2-medium and incubated for 6 days. 
Endothelial cells were harvested using accutase, and cell 
number and viability measured using ViaCount stain and 
Guava EasyCyte flow cytometer (Millipore). For Du145 
tumour cells, BM-MSC CM was added at 1:1 ratio (v/v) 
with RPMI media for 3 days prior to measuring cell 
number and viability as above. These measurements were 
performed in triplicates. To assess cell motility, a confluent 
monolayer of endothelial or tumour cells in 24 well plates, 
were subject to a single vertical scratch, using a 200μl 
pipette tip. BM-MSC CM was added as above, and wells 
were microscopically monitored up to 24 hours. The width 
of the scratch in duplicate wells was measured at 4 points 
for each well, using Image-J (National Institutes of Health, 
Bethesda, MD, USA), and the rate of monolayer recovery 
plotted as relative to the original scratch width (% closure) 
as described [29]. Formation of endothelial tubules was 
performed as described [29], with endothelial cells 
(20,000/well) added in triplicate to monolayers of BM-
MSC that had been previously treated with exosomes or 
TGFβ for 4days. After a further 6 days culture, structures 
formed by endothelial cells were visualised by immune-
fluorescent labelling of CD31 (SantaCruz). The total area 
occupied by CD31-positive structures was quantified 
using the free-hand selection tool in Image-J to calculate 
the area occupied by stained cells in each well. Data show 
the average from triplicate wells per treatment, and are 
representative of three such experiments.
Tumour cell and BM-MSC heterotypic spheroids
Tumour cells (control or Rab27aKD) were incubated 
alone or together with BM-MSC at a ratio of 4 tumour 
cells:1 MSC, in Poly(2-hydroxyethyl methacrylate) 
haema (Sigma, Dorset, UK) coated 96-well, “u”-bottom 
plates. The medium used consisted of 1:1 ratio (v/v) of 
RPMI and DMEM (low glucose) in 10% FBS. The total 
number of cells was 104 per well. After 4 days, the cells 
had established 3D-spheroidal structures. There was no 
significant difference in the size or structure of the spheroids 
at these time points (not shown). To evaluate potential 
changes in invasive behaviour of the cells, spheroids were 
transferred to fresh uncoated 96 well plates and Matrigel™ 
(Corning, Flintshire, UK) was added (100μl/well). After 
setting at 37oC for 30 min, medium was added, and the 
wells monitored microscopically for 4 days thereafter. To 
estimate the magnitude of invasion out from the spheroid, 
the free-hand selection tool in Image-J was used draw the 
circumference of the central sphere. This was subtracted 
from the circumference of the region occupied by 
invading cells. This gives an approximation of the area of 
Matrigel™ invaded by cells, as it does not take account of 
the volume aspect of the 3D culture, and is likely therefore 
to underestimate the true differences across the treatments.
Statistical analysis
Statistic analyses were performed using Prism-4 
software V4.03 (Graph Pad,San Diego, CA, USA). In 
experiments with more than two experimental groups, one-
way ANOVA with Tukey’s post-test was used, except for 
migration and in vivo experiments where a two-way ANOVA 
with Bonferroni post-test was used. Experiments with two 
experimental groups were evaluated using Student’s t-test. 
P-values less than 0.05 are considered significant *P < 0.05, 
**P < 0.01, ***P < 0.001, ****P < 0.0001.
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